NASDAQ:QTNT - Quotient Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.25
  • Forecasted Upside: 112.64 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.35
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Quotient Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QTNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QTNT

Average Price Target: $9.25
▲ +112.64% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Quotient in the last 3 months. The average price target is $9.25, with a high forecast of $13.50 and a low forecast of $5.00. The average price target represents a 112.64% upside from the last price of $4.35.

Buy

The current consensus among 2 polled investment analysts is to buy stock in Quotient.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$5.00Medium
8/19/2020Jefferies Financial GroupReiterated RatingBuy$13.50Low
3/5/2019Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.50High
5/30/2018BTIG ResearchReiterated RatingBuy$10.00Low
5/20/2018BTIG ResearchSet Price TargetBuy$10.00Medium
3/27/2018BTIG ResearchReiterated RatingBuy$10.00Low
11/1/2017BTIG ResearchReiterated RatingBuy$12.00N/A
11/1/2017Jefferies Financial GroupLower Price TargetBuy$15.00 ➝ $13.00N/A
8/31/2017BTIG ResearchReiterated RatingBuy ➝ Buy$12.00High
4/18/2017BTIG ResearchReiterated RatingBuy$22.00High
1/6/2017Jefferies Financial GroupReiterated RatingBuy$16.00N/A
(Data available from 6/18/2016 forward)
Quotient logo
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Read More

Today's Range

Now: $4.35
Low: $4.18
High: $4.45

50 Day Range

MA: $4.00
Low: $3.48
High: $4.45

52 Week Range

Now: $4.35
Low: $3.41
High: $8.77

Volume

1,715,065 shs

Average Volume

707,677 shs

Market Capitalization

$441.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Quotient?

The following sell-side analysts have issued stock ratings on Quotient in the last twelve months: Jefferies Financial Group Inc., The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for QTNT.

What is the current price target for Quotient?

2 Wall Street analysts have set twelve-month price targets for Quotient in the last year. Their average twelve-month price target is $9.25, suggesting a possible upside of 112.6%. Jefferies Financial Group Inc. has the highest price target set, predicting QTNT will reach $13.50 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $5.00 for Quotient in the next year.
View the latest price targets for QTNT.

What is the current consensus analyst rating for Quotient?

Quotient currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QTNT will outperform the market and that investors should add to their positions of Quotient.
View the latest ratings for QTNT.

What other companies compete with Quotient?

How do I contact Quotient's investor relations team?

Quotient's physical mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company's listed phone number is 011-41-22-716-9800. The official website for Quotient is www.quotientbd.com.